GlassScriptPhysician profile
Allyson Michelle Wehrheim
NPI 1043705148
$3,256.15
in general payments reported to CMS, 2019-2025
41 companies · $749 in 2025
The $749 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $481 · 2023: $814 · 2024: $747 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $303.64 | 2021-2025 | |
| Amgen INC. | $254.35 | 2021-2025 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $234.46 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $189.72 | 2022 | |
| Inari Medical, INC. | $167.48 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $148.86 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Mylan Specialty L.P. | $129.31 | 2021-2024 | Yupelri |
| Pfizer INC. | $122.57 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.37 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $94.98 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.31 | 2022-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $73.08 | 2022-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $70.96 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Viatris Specialty LLC | $65.78 | 2025 | Yupelri |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Wehrheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.